Allianz Asset Management GmbH Buys 69,359 Shares of CareDx, Inc. (NASDAQ:CDNA)

Allianz Asset Management GmbH increased its position in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 145.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 117,075 shares of the company's stock after acquiring an additional 69,359 shares during the period. Allianz Asset Management GmbH owned approximately 0.21% of CareDx worth $2,078,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Sterling Capital Management LLC increased its holdings in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after buying an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of CareDx by 553.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after purchasing an additional 3,322 shares during the last quarter. State of Wyoming bought a new position in shares of CareDx during the 4th quarter valued at $91,000. Morse Asset Management Inc bought a new position in shares of CareDx during the 1st quarter valued at $103,000. Finally, Balance Wealth LLC bought a new position in shares of CareDx during the 1st quarter valued at $189,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 target price on shares of CareDx in a report on Monday, May 5th. Stephens reaffirmed an "overweight" rating and set a $40.00 target price on shares of CareDx in a report on Monday, May 5th. Wall Street Zen lowered shares of CareDx from a "hold" rating to a "sell" rating in a report on Saturday. Craig Hallum cut their price target on shares of CareDx from $40.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Finally, The Goldman Sachs Group dropped their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $29.33.

Insider Activity

In other CareDx news, Director Peter Maag sold 10,000 shares of the business's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $18.58, for a total transaction of $185,800.00. Following the completion of the sale, the director directly owned 308,846 shares in the company, valued at $5,738,358.68. The trade was a 3.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine Cournoyer sold 29,136 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the completion of the transaction, the director owned 37,045 shares in the company, valued at $591,238.20. This trade represents a 44.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 125,797 shares of company stock valued at $2,191,084 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

CareDx Price Performance

NASDAQ CDNA traded down $0.06 during trading hours on Friday, reaching $12.22. 970,322 shares of the company's stock traded hands, compared to its average volume of 2,184,899. CareDx, Inc. has a 52-week low of $10.96 and a 52-week high of $34.84. The firm has a market cap of $680.41 million, a PE ratio of 10.63 and a beta of 2.22. The firm has a 50-day simple moving average of $17.41 and a 200 day simple moving average of $18.80.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The company had revenue of $84.69 million during the quarter, compared to analysts' expectations of $84.56 million. During the same period last year, the company posted ($0.03) EPS. CareDx's revenue was up 17.6% on a year-over-year basis. Sell-side analysts forecast that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.